Healthcare costs of urinary tract infections and genital mycotic infections among patients with type 2 diabetes mellitus initiated on canagliflozin: a retrospective cohort study

References

• International Diabetes Federation. IDF Atlas. Brussels, 2015, http://www.idf.org/diabetesatlas. Accessed June 23, 2016
   Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States; Atlanta: Centers for Disease Control and Prevention; 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed June 23, 2016
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2015 Diabetes Care 2015;38(1Suppl):S41-S8
   Web of Science ®Google Scholar
• Rowley WR, Bezold C. Creating public awareness: state 2025 diabetes forecasts. Popul Health Manag 2012;15:194-200
   PubMed Web of Science ®Google Scholar
• de Leon EM, Jacober SJ, Sobel JD, et al. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis 2002;2:1
   PubMed Web of Science ®Google Scholar
• Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infectious disease hospitalisation and outcome. Diabetologia 2007;50:549-54
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008;26:77-82
   Google Scholar
• Williams R, Van Gaal L, Lucioni C, et al. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45:S13-S17
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ward AJ, O'Brien JA. Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25:476-81
   PubMed Web of Science ®Google Scholar
• Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 2013;19:421-30
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-46
   PubMed Web of Science ®Google Scholar
• Yu S, Fu AZ, Qiu Y, et al. Disease burden of urinary tract infections among type 2 diabetes mellitus patients in the U.S. J Diabetes Complications 2014;28:621-6
   PubMed Web of Science ®Google Scholar
• Alva ML, Gray A, Mihaylova B, et al. The impact of diabetes related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med 2015;32:459-66
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 2013;45:253-61
   PubMed Web of Science ®Google Scholar
• Ward A, Alvarez P, Vo L, et al. Direct medical costs of complications of diabetes in the United Stats: Estimated for event-year and annual state cost (USD 2012) J Med Econ 2014;17:176-83
   PubMedGoogle Scholar
• Nitzan O, Elias M, Chazan B, et al. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes 2015;8:129-36
   PubMed Web of Science ®Google Scholar
• Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology. Diabetes Ther 2014;5:355-66
   PubMed Web of Science ®Google Scholar
• Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 2012;14:539-45
   PubMed Web of Science ®Google Scholar
• Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care 2013;36:2154-61
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
   PubMed Web of Science ®Google Scholar
• Wilding JP, Charpentier G, Hollander P, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013;67:1267-82
   PubMed Web of Science ®Google Scholar
• Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
   PubMed Web of Science ®Google Scholar
• Forst T, Guthrie R, Goldenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014;16:467-77
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care 2015;38:355-64
   PubMed Web of Science ®Google Scholar
• Nardolillo A, Kane MP, Busch RS, et al. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes 2014;7:25-30
   PubMedGoogle Scholar
• Ji L, Han P, Liu Y, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab 2015;17:23-31.
   PubMed Web of Science ®Google Scholar
• Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD, Fung A, et al. Genital mycotic infections with canagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014;30:1109-19
   PubMed Web of Science ®Google Scholar
• Nicolle LE, Capuano G, Fung A, et al. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014;126:7-17
   PubMed Web of Science ®Google Scholar
• Geerlings S, Fonseca V, Castro-Diaz D, et al. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract 2014;103:3733-81
   Web of Science ®Google Scholar
• Davies MJ, Kushner P, Vijapurkar U, et al. Incidence of GMI and UTI over time in patients with T2DM treated with canagliflozin over 2 years [abstract]. J Gen Intern Med 2015;30:S61-S62
   Google Scholar
• Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(1ASuppl):5S-13S
   Web of Science ®Google Scholar
• Grandy S, Fox KM, Hardy E, et al. Prevalence and recurrence of urinary tract and genital infections among adults with and without type 2 diabetes mellitus in the general population: a longitudinal cohort study. J Diabetes Res Clin Metab 2013;2:5
   Google Scholar
• Hirji I, Andersson SW, Guo Z, et al. Incidence of genital infection among patients with type 2 diabetes in the UK General Practice Research Database. J Diabetes Complications 2012;26:501-5
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013;125:33-46
   PubMed Web of Science ®Google Scholar
• Grigoriou O, Baka S, Hassiakos et al. Prevalence of clinical vaginal candidiasis in a university hospital and possible risk factors. Eur J Obstet Gynecol Reprod Biol 2006;126:121-5
   PubMed Web of Science ®Google Scholar
• Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol 2010;172:1092-7
   PubMed Web of Science ®Google Scholar
• D’Agostino R Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar
• Parsons L. Reducing bias in a propensity score matched-pair sample using Greedy Matching techniques. 26th Annual SAS User Group International Conference, Long Beach, CA, 2001; pp. 214-16, 22-25 April 2001
   Google Scholar
• Ho DE, Imai K, King G, et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Analysis 2007;15:199-236
   Web of Science ®Google Scholar
• Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care 2008;14:15-24
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27. Note: For detailed description of Version 3.7, see URL http://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed 10 August 2015
   PubMed Web of Science ®Google Scholar
• Hirji I, Guo Z, Andersson SW, et al. Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD). J Diabetes Complications 2012;26:513-16
   PubMed Web of Science ®Google Scholar
• Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in men. J Urol 2005;173:1288-94
   PubMed Web of Science ®Google Scholar
• Worley K, Bell KF, Xu Y, et al. Resource utilization and health care costs among diabetics with urinary tract infections in a commercially insured population. J Clin Outcomes Manage 2012;19:539-50
   Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• Nyirjesy P, Zhao Y, Ways K, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012;28:1173-8
   PubMed Web of Science ®Google Scholar